Bristol’s Orencia sBLA For Juvenile Idiopathic Arthritis Accepted For FDA Review
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.’s NICE, meanwhile, concludes the biologic is not cost effective for treatment of rheumatoid arthritis following a TNF inhibitor.